Skip to content

Xylometazoline During Nasal Flexible Bronchoscopy

Effect of Xylometazoline Administration During Nasal Flexible Bronchoscopy: A Double Blind, Randomized, Placebo-controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03424889
Acronym
VAIN
Enrollment
148
Registered
2018-02-07
Start date
2018-06-01
Completion date
2019-01-31
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchoscopy

Keywords

Bronchoscopy, Lignocaine, Anaesthesia

Brief summary

Flexible bronchoscopy is a commonly performed procedure and is usually performed transnasally. The optimal topical anesthesia regimen for bronchoscopy is investigational. Topical Vasoconstrictors like xylometazoline produce decongestion of nasal mucosa and may make insertion of bronchoscope easier. The addition of topical vasoconstrictor to lignocaine may have advantage in terms of patient comfort and for reducing local complications. Although evaluated in the settings of nasal endoscopy and nasotracheal intubation, randomized trials on the role of topical vasoconstrictors during flexible bronchoscopy are not available. The aim of this randomized trial is to study the effect of topical nasal xylometazoline administration during flexible bronchoscopy.

Detailed description

Study design: Randomized double-blind placebo controlled study Study setting: Bronchoscopy room in Department of pulmonary medicine and sleep disorders at AIIMS, New Delhi Sample size: 200 patients (100 in each arm) Inclusion criteria: a) All adults \> 18 years of age undergoing flexible bronchoscopy via nasal route Exclusion criteria: 1. Uncontrolled hypertension 2. coronary artery disease b) Pregnancy c) refusal of consent d) Hypoxemia (oxygen saturation \[by pulse oximetry\] \< 92% with Fio2 of ≥ 0.3 e) Bronchoscopy not performed by nasal route f) Bronchoscopy performed through an artificial airway Randomisation: Computer generated Block randomisation with block size of 10 will be used to generate list of random numbers based on which subjects will be allocated to either of the groups. Procedure of study The operator, assistant, drug administrator and outcomes assessor will be blinded. Patients meeting eligibility criteria will be randomized to receive either study drug Xylometazoline (0.1% nasal drops) (Otrivin, Novartis) (3 drops into each nostril) or 0.9% saline (3 drops into each nostril) placebo. This will be administered as ten minutes before bronchoscopy. This will be followed by the standard topical anesthesia procedure followed in our institution involving 5ml of 2% lignocaine gel into the nostril and 4 sprays of 10% lignocaine to the pharynx. Nebulized lignocaine shall not be administered. Transnasal flexible bronchoscopy will be performed with additional 1% lignocaine solution administered as spray as you go method. All diagnostic procedures or airway inspection procedures will be included. Patients shall undergo hemodynamic monitoring throughout the procedure. Procedures shall be performed without administration of upfront sedation and intraprocedural sedation shall be at the discretion of the operator. Data will be recorded on a predesigned proforma. Baseline patient characteristics will be compared between the two groups. Categorical variables will be summarised by frequency (%) and chi-square test of proportion will be used to compare between the two groups.Quantitative variables will be summarised by mean±SD or median(IQR),as appropriate. Student's t-test or Wilcoxon rank sum test as appropriately be used to compare distribution of quantitative variables between the two groups. Stata statistical software will be used for data analysis.

Interventions

Nasal administration of Xylometazoline

DRUGSaline

Nasal administration of 0.9% Saline

Sponsors

All India Institute of Medical Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

Concealed envelopes

Intervention model description

Randomized, double blind, placebo controlled

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

\- All adults \> 18 years of age undergoing flexible bronchoscopy via nasal route

Exclusion criteria

* Uncontrolled hypertension * coronary artery disease * Pregnancy * refusal of consent * Hypoxemia (oxygen saturation \[by pulse oximetry\] \< 92% with Fio2 of ≥ 0.3 * Bronchoscopy not performed by nasal route * Bronchoscopy performed through an artificial airway

Design outcomes

Primary

MeasureTime frameDescription
Operator rated difficulty in nasal bronchoscope negotiation (VAS)At study completion approximately 4 monthsVisual Analogue scale

Secondary

MeasureTime frameDescription
Assistant rated Faces Pain scale for discomfort on nasal bronchoscope insertionAt study completion approximately 4 months10 point scale divided into six categories
Patient rated nasal pain on procedure completion (VAS)At study completion approximately 4 monthsVisual Analogue scale
Operator rated nasal mucosal trauma (VAS)At study completion approximately 4 monthsVisual Analogue scale
ComplicationsAt study completion approximately 4 monthsProportion of patients developing complications

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 24, 2026